397 related articles for article (PubMed ID: 32028670)
21. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
[TBL] [Abstract][Full Text] [Related]
22. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.
Yessoufou A; Wahli W
Swiss Med Wkly; 2010; 140():w13071. PubMed ID: 20842602
[TBL] [Abstract][Full Text] [Related]
23. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
Hong F; Xu P; Zhai Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
[TBL] [Abstract][Full Text] [Related]
24. Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system.
Genini D; Catapano CV
J Recept Signal Transduct Res; 2006; 26(5-6):679-92. PubMed ID: 17118805
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).
Scatena R; Martorana GE; Bottoni P; Giardina B
IUBMB Life; 2004 Aug; 56(8):477-82. PubMed ID: 15545227
[TBL] [Abstract][Full Text] [Related]
26. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology.
Scatena R; Bottoni P; Martorana GE; Vincenzoni F; Botta G; Pastore P; Giardina B
Eur J Pharmacol; 2007 Jul; 567(1-2):50-8. PubMed ID: 17499714
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
Sertznig P; Seifert M; Tilgen W; Reichrath J
Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
Guan Y; Breyer MD
Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
[TBL] [Abstract][Full Text] [Related]
29. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
30. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.
Schoonjans K; Staels B; Auwerx J
Biochim Biophys Acta; 1996 Jul; 1302(2):93-109. PubMed ID: 8695669
[TBL] [Abstract][Full Text] [Related]
31. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects.
Auwerx J; Schoonjans K; Fruchart JC; Staels B
J Atheroscler Thromb; 1996; 3(2):81-9. PubMed ID: 9226459
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.
Zoete V; Grosdidier A; Michielin O
Biochim Biophys Acta; 2007 Aug; 1771(8):915-25. PubMed ID: 17317294
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
Gupta M; Mahajan VK; Mehta KS; Chauhan PS; Rawat R
Arch Dermatol Res; 2015 Nov; 307(9):767-80. PubMed ID: 25986745
[TBL] [Abstract][Full Text] [Related]
34. [PPAR family and its relationship to metabolic syndrome].
Zhang XY; Chen LH; Guan YF
Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment?
Weindl G; Schäfer-Korting M; Schaller M; Korting HC
Drugs; 2005; 65(14):1919-34. PubMed ID: 16162018
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
37. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
38. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
39. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
Sertznig P; Seifert M; Tilgen W; Reichrath J
J Cell Physiol; 2007 Jul; 212(1):1-12. PubMed ID: 17443682
[TBL] [Abstract][Full Text] [Related]
40. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
Menendez-Gutierrez MP; Roszer T; Ricote M
Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
